The transcription factor Dmp1 is a Ras/HER2-activated haplo-insufficient tumor suppressor that activates the Arf/p53 pathway of cell cycle arrest. Recent evidence suggests that Dmp1 may activate p53 independently of Arf in certain cell types. Here we report findings supporting this concept with the definition an Arf-independent function for Dmp1 in tumor suppression. We 
Summary
The transcription factor Dmp1 is a Ras/HER2-activated haplo-insufficient tumor suppressor that activates the Arf/p53 pathway of cell cycle arrest. Recent evidence suggests that Dmp1 may activate p53 independently of Arf in certain cell types. Here we report findings supporting this concept with the definition an Arf-independent function for Dmp1 in tumor suppression. We found that Dmp1 and p53 can interact directly in mammalian cells via the carboxyl-terminus of 
Introduction
Upon cellular stresses, such as DNA damage, oncogene activation, and hypoxia, the tumor suppressor p53 is activated and initiates a transcriptional program that induces DNA repair, cell cycle arrest, apoptosis, or autophagy (1) (2) (3) . This stress signaling plays critical roles in the prevention of tumor formation and, indeed, p53-null mice or p53 knock-in mice that express mutant p53 are highly prone to tumor development (4) . A central regulator of the p53 pathway is the Mdm2 protein (Hdm2 in humans) that inhibits transcriptional activity, nuclear localization, and protein stability of p53 (5) (6) (7) . Homozygous deletion of Mdm2 results in embryonic lethality at the blastocyst stage due to unrestricted apoptosis. Deletion of p53 abrogates this effect, indicating the critical in vivo function of Mdm2 is the negative regulation of p53 activity (7) .
The Mdm2 (and also Hdm2) gene is regulated by p53 through direct binding of the protein to the p53-responsive elements located within the P2 promoter (7) . Mutations in TP53 that disrupt p53 function occur in 50% of human cancers (8) ; the alteration of regulators for p53 is found in most of the remaining 50%. The Hdm2 gene is amplified in ~35% of human sarcomas and ~7% of all cancers without TP53 mutation, but the protein is overexpressed in 40-80% of late-stage metastatic cancers in the absence of gene amplification (7, 9) .
The activity of Mdm2 is negatively regulated by p19 Arf (p14 ARF in humans) in response to oncogenic stress (10) (11) (12) (13) . p19
Arf is an alternative reading frame gene product generated from the Ink4a/Arf locus which also encodes the cyclin-dependent kinase inhibitor p16 Author Manuscript Published OnlineFirst on February 13, 2012; DOI: 10.1158/0008-5472. CAN-11-2410 harmful growth-promoting signals forces early-stage cancer cells to undergo p53-dependent andindependent cell cycle arrest, apoptosis, or autophagy providing a powerful mode of tumor suppression (10) (11) (12) (13) . The Arf promoter monitors latent oncogenic signals in vivo, and thus Arfnull mice are also highly prone to spontaneous tumor development (14, 15) . Arf is regulated at both transcriptional and protein levels (16) (17) (18) (19) . The Arf promoter is directly activated by E2Fs and Dmp1 while it is repressed by overexpression of nuclear proteins such as Bmi1, Twist, Tbx2/3, and Pokemon (16, 17) . Dmp1 (cyclin D binding myb-like protein 1; Dmtf1) is a tumor suppressor that is deleted in ~40% of human non-small cell lung carcinomas (20) (21) (22) (23) (24) . Mitogenic signals from oncogenic Ras and HER2/neu have been shown to activate the Dmp1 promoter, while physiological mitogens as well as genotoxic stimuli mediated by NF-κB cause repression (25-28). It has been considered that the Dmp1 protein acts as a tumor suppressor by directly activating the Arf promoter, and thereby inducing Arf-, p53-dependent cell cycle arrest (16, 21, 22 mice with no significant differences in the survival between the two cohorts, suggesting that Dmp1 is haplo-insufficient for tumor suppression (22, 23, 28) . In Eµ-Myc lymphomas, the combined frequencies of p53 mutation and Arf deletion in mice of Dmp1
In this study, we searched for binding partners for the Dmp1 protein to explain the Arfindependent function of Dmp1 in tumor suppression. We show that Dmp1 physically interacts with p53 to neutralize the activity of Hdm2 on p53's ubiquitination, nuclear localization, and transcription. We also demonstrate that Dmp1 has Arf-independent mechanisms of p53 activation in vivo. We propose that the physical interaction between Dmp1 and p53 will synergize with Arf promoter activation by Dmp1 to enhance the activity of the p53 pathway. 
Materials and Methods
Cell culture, retrovirus preparation, and infection NIH 3T3, H1299, A549, and U2OS cells were cultured and transfected as described previously (16, 20) . Passage 6 Arf; p53-double knockout MEFs were received from Drs. C. Sherr and M.
Roussel. For preparation of retroviruses, human kidney 293T cells were transfected with a helper ecotropic retrovirus plasmid defective in psi-2 packaging sequences, together with pMSCV-IRES-puro vectors containing Dmp1, Dmp1 mutant, or p53 cDNA (16) .
Detection of endogenous Dmp1-p53 interaction
Subconfluent U2OS cells were co-treated with 2 μM etoposide (Toposar®, Teva) and 25 μM MG-132 for 6 hrs, then harvested in EBC buffer. 1 mg of total protein was immunoprecipitated with 4 μg of antibodies to Dmp1 (RAD to the full-length His-Dmp1 [29] , RAX [26] or RAZ
[24]), antibodies to p53 (sc-126, sc-6243), or control immunoglobulins, followed by incubation with protein G-sepharose and extensive wash with lysis buffer (30) . Sites of antibody bindings were visualized by sc-126 for p53 and RAD for Dmp1, followed by Trueblot TM secondary antibodies (eBioscience). Endogenous Dmp1-p53 interaction was also studied with 1 mg of mouse thymus lysates injected with 0.6 mg/30 g etoposide.
In cell p53 ubiquitination assays
This assay was adapted from Li et al (31) . H1299 cells were transfected with His-tagged ubiquitin, p53, Mdm2, and increasing amounts of Dmp1. Cells were treated with 25 μM proteasome inhibitor MG-132 (Calbiochem) for six hrs prior to harvesting to prevent degradation were then centrifuged at 10,000g for 2 minutes at 4°C and the supernatant (unbound) lysate was removed and saved. The Ni-NTA resin was washed four times with 800 µL EBC without EDTA. His-tagged proteins were eluted from the Ni-NTA agarose by incubating in EBC buffer at 100ºC for 5 minutes. The samples were then centrifuged at 10,000g for 2 minutes at 4°C and the supernatant (immunoprecipitated protein) was analyzed by Western blotting using antibodies for p53, Dmp1, Hdm2, and Actin.
Induction of DNA damage response by doxorubicin injection in mice
Arf-null mice were obtained from NCI Mouse Repository. p53-null mice were purchased from the Jackson Laboratory (Bar Harbor, Maine). Six-week-old wild-type, Arf
, and p53 -/-mice (all C57BL/6) were intravenously injected with 0.6 mg doxorubicin/30 g mouse for 0, 2, and 4 hrs, after which they were sacrificed, and thymi and lungs were harvested. Apoptosis was evaluated in vivo using antibodies to cleaved caspase 3 (Cell Signaling). For p53 target genes, and bbc3 promoters by realtime PCR, Taqman assays were custom designed by ABI to detect target sequences using mouse β-actin genomic DNA as an internal control. All procedures involving mice were approved by IACUC. 
Results

Dmp1 physically interacts with p53
Published studies indicate that Dmp1 regulates p53 levels in vivo since Dmp1-null tumors have significantly decreased incidence of p53 mutation (22, 23). Thus, the half-life of p53 was studied by activating Dmp1:ER in MCF10A cells (ARF-null), and found that it was extended from 41 minutes to 3.5 hrs (Supplementary Fig. S1 ). To identify which key components of the Arf-Mdm2-p53 tumor suppressor pathway interact with Dmp1, the protein was transiently coexpressed with p53, Mdm2, p19
Arf , or c-Myb in 3T3 cells ( Fig. 1A, B; Supplementary Fig. S2A ; the input protein levels are shown in Supplementary Fig. 3 ). Immunoprecipitation with FLAG antibody showed that only p53 interacted with Dmp1 among these four proteins. Reciprocal immunoprecipitation with HA antibody verified that Dmp1 was co-immunoprecipitated (co-IP) with p53 (Fig. 1B) . Physical interaction of Mdm2-p53 was also confirmed by co-IP under the same experimental condition. Of note, the presence of Dmp1 did not interfere with Mdm2-p53 binding, suggesting that Dmp1 binds to p53 using a domain distinct from the Mdm2-binding region (Fig. 1B , last lane). Additionally, Dmp1 did not interact with c-Myc, E2F2, or E2F3, further demonstrating the specificity of Dmp1-p53 binding ( Supplementary Fig. S2B, C) .
Next, the interaction of endogenous human DMP1 (hDMP1) with p53 was examined using U2OS cell lysates treated with the topoisomerase inhibitor etoposide. The hDMP1 protein was co-immunoprecipitated with p53 using two different antibodies to p53 ( Figure S4) . To determine whether the Dmp1-p53 interaction was direct or indirect, purified proteins from baculovirus-infected Sf9 cell lysates were used (Fig. 1D) . A significant amount (~5% of input) of Flag-Dmp1 was identified in complex with HA-p53 in vitro. Reciprocal immunoprecipitation showed that HA-p53 (~5% of input) was pulled down with an antibody to Dmp1 (Fig. 1D) . We also confirmed direct interaction between Mdm2 and p53, but not Dmp1 and Mdm2 (Fig. 1D , middle panels). Together, our data show Dmp1 physically interacts with p53, but not to p19 Arf or Mdm2.
Mapping of p53-bindig domain on Dmp1 and Dmp1-binding domain on p53
Mapping the p53-bindig domain on Dmp1 was accomplished by co-expressing Dmp1 mutants with wild-type p53 in Sf9 and 3T3 cells. We found the Dmp1 mutants M5, M6, M7 M8, and M9 (20) were unable to interact with p53, suggesting that amino acid residues 1-380 are vital to Dmp1's interaction with p53 ( Fig. 2A, B) . Specifically, the DNA-binding domain of Dmp1 (amino acids 87-380) is considered to play a major role in the Dmp1-p53 interaction since the M10 mutant bound to p53 at the same level as wild-type. The p53-interaction domain on Dmp1 was mapped to amino acids 87-380 in NIH 3T3 cells ( Supplementary Fig. S5A, C) . Conversely, the Dmp1-binding domain was mapped to amino acid residues 290-360 of p53 (nuclear localization signal and tetramerization domain ( 
Dmp1 antagonizes ubiquitination of p53 by Mdm2
Mdm2 (or Hdm2) has been reported to inactivate p53 by 1) accelerating ubiquitin-mediated degradation of p53, 2) inhibiting nuclear import of p53 to the nucleus, and/or by 3) inhibiting transcriptional activity of p53 (5) (6) (7) 13) . To assess the effect of Dmp1 expression on p53 ubiquitination by Hdm2, H1299 cells were co-expressed with His-tagged ubiquitin, p53, Hdm2, and increasing amounts of Dmp1. Ubiquitinated proteins were brought down with Ni-NTA resin, and samples were analyzed by Western blotting. Results show that Dmp1 overexpression decreased p53 polyubiquitination by Hdm2 in the presence or absence of proteasome inhibitor ( Fig. 3A; Supplementary Fig. S7 ). H1299 cells transfected with shRNA to p14 ARF also showed significant inhibition of p53 polyubiquitination by Dmp1 indicating that the effect was ARFindependent ( Fig. 3B) . To study the effects of endogenous Dmp1 on p53 stability, hDMP1 was knocked down by specific shRNA (23). Cells depleted for DMP1 exhibited over a 60% reduction in endogenous p53 protein levels compared to vector ( Supplementary Fig. S8A ) while p53 transcript levels remained unchanged ( Supplementary Fig. S8B ). Therefore, modulation of p53 levels by Dmp1 does not take place at the transcriptional level. Furthermore, endogenous p53 ubiquitination was drastically increased (Supplementary Fig. S8C) co-expression of Hdm2 and Dmp1 significantly inhibited Hdm2-mediated ubiquitination of p53 in dose-dependent fashion (Fig. 3C, Supplementary Fig. S9 ). Conversely, auto-ubiquitination of Hdm2 was not inhibited by Dmp1 (Supplementary Fig. S10 ) suggesting that Dmp1's mode of action involves its direct binding with p53 and does not function as a general/non-specific inhibitor of Hdm2's ubiquitin ligase activity. The M6 and M7 Dmp1 mutants that do not bind to p53 had little effect in p53 ubiquitination in vitro, indicating that direct physical interaction between Dmp1 and p53 is essential for Dmp1 to interfere with Hdm2 activity (Fig. 3C) . To observe the effect of Dmp1-loss on p53 levels in vivo, 5-week-old Dmp1 -/-and pure wild-type mice were treated by intravenous injection of doxorubicin for four hours. The animals were sacrificed, the thymus resected, and total protein prepared for analysis by PAGE. Steady -state p53 levels in untreated animals were 50% lower in mice of Dmp1-null background compared to wild-type. A 30% reduction in total p53 was observed in the thymus from Dmp1 target gene products were proportionate to the levels of phosphorylated p53 ( Figure 3D , 5th -6th lanes). These data indicated that Dmp1 not only plays critical roles in setting basal p53 levels in tissues, but also is involved in the activation of p53 in response to DNA-damage.
Dmp1 antagonizes nuclear export of p53 by Hdm2
Next, we investigated whether Dmp1 altered the localization of p53. H1299 cells were cotransfected with GFP, p53, Hdm2, and/or Dmp1, probed for p53, and analyzed by confocal microscopy (Fig. 4A) . As anticipated, Hdm2 expression resulted in an absolute reduction in p53 (Fig. 4A, 2 nd panels). This effect was rescued by concurrent expression of Dmp1 (Fig. 4A , the 3 rd panels) while the M7 mutant was unable to reverse the negative effects of Hdm2 (Fig. 4A , the 4 th panels). Increased nuclear localization of p53 by Dmp1 was verified in endogenous proteins since MCF7 cells (ARF-null) depleted of hDMP1 by shRNA resulted in nuclear exclusion of p53, while, in control cells, p53 was retained in the nucleus (Supplementary Fig. S11 ).
Subcellular localization of p53 was also studied in A549 cells (ARF-null) co-expressed with p53-ZsGreen, Dmp1, and Hdm2 (Fig. 4B) Synergism between Dmp1 and p53 on p53 target gene transcription in Arf-deficient cells Next Arf; p53 double knockout (DKO) cells were transiently co-expressed with wild-type p53 and Dmp1 (and its mutants) to study the consequences on p53 function. We saw significant accumulation of p53 in cells co-expressing p53 and Dmp1 wild-type or the M11 mutant that does not bind to DNA, but not in those expressing p53 plus the M7 mutant that does not bind to p53 (Fig. 5A) (20) . The increase in p53 levels upon co-expression of Dmp1 correlated with synergistic activation of the p21 Cip1/Waf1 promoter luciferase construct in Arf; p53 double-knockout MEFs, (Fig.   5B, left panel) . The Dmp1 M11 mutant that does not bind to DNA (20) also synergized with p53 on the p21 promoter activation (Fig. 5B, right 
p53 and Dmp1 was independent of DNA-binding of the latter. Since the M7 mutant did not contribute to the stability of p53, it had no effect on p53-mediated transactivation of the p21 promoter (Fig. 5B, right panel) mRNA by real-time PCR (Fig. 5C) . Synergism between p53 and Dmp1 was also demonstrated by real-time PCR for bbc3 (puma) in Arf
MEFs, albeit to a lesser extent (Fig. 5C, right) . Thus, synergistic activation of the p21 and bbc3 promoters by Dmp1 (wild-type and M11 mutant) and p53 was a consequence of increased p53 levels.
We then tail-injected doxorubicin in wild-type and Dmp1-null mice, harvested the thymus at 0 and 4 hrs post-treatment, and binding of p53 to target gene (p21
Cip1
and bbc3) promoters was studied by chromatin immunoprecipitation followed by real-time PCR (Fig. 5D ). Significant binding of p53 (0.5% of input levels) to the p21 Cip1 and bbc3 promoters was found in wild-type, but not in Dmp1-null thymus, suggesting that Dmp1 is indispensable for p53 binding to these promoters in vivo. Together, our data indicate that 1) expression of Dmp1 interferes with the known activities of Hdm2 on p53's ubiquitination and nuclear localization in an Arf-independent fashion, and that 2) p53-binding to target genes in Dmp1-dependent.
Arf-independent function of Dmp1 on p53 in vivo
To demonstrate the Arf-independent function of Dmp1 on p53 in vivo, we injected doxorubicin into wild-type, Arf-null, Dmp1-null, and p53-null mice, harvested the thymus at 2 hr intervals, and studied the expression of the p53 targets p21 immunohistochemistry (Fig. 6) . Thymus was chosen as a target tissue since Dmp1 was highly expressed in the medulla in our previous histochemical studies (26). Cleaved caspase 3 was detectable in thymic medulla of wild-type mice 6 hrs after injection of doxorubicin, indicating apoptotic cell death (Fig. 6A, wt) . Activation of p53 was confirmed by pSer6 and pSer15-specific antibodies (data not shown). Cleaved caspase 3 staining was significantly decreased in the thymus from Arf thymus even 4-6 hrs after injection of doxorubicin (Fig. 6B) . These data were confirmed by immunohistochemical staining of thymic tissues with p21 and bbc3-specific antibodies (Fig. 6C) . Likewise, p21 and bbc3 induction by doxorubicin was more seriously Supplementary Fig. S12A, B) , eliminating the possibility this effect is cell type specific. Together, our data demonstrate Arf-independent activation of p53 by Dmp1 in response to genotoxic drug in vivo. The current model for the mechanism of regulation of p53 by Dmp1 is summarized in Fig. 6D . However, inhibition of ubiquitination and nuclear export of p53 by Dmp1 are considered to be Arfindependent since they were found in cells where p14 ARF was knocked down or deleted.
Synergistic activation of the p21
Cip1/Waf1
promoter by p53 and Dmp1 was also Arf-independent since it was found p53; Arf-null cells. These Arf-independent mechanisms of p53 modulation by physically interacts with p53 (32). Furthermore, most p53-interacting proteins that bind to the Cterminus of p53 (e.g. YB-1, YY1, or RelA) negatively regulate its function whereas Dmp1 regulates p53 positively in terms of stabilization and nuclear localization (30, 32) . Thus, Dmp1 is a critical antagonist of Mdm2 in regulating the activity of p53.
The current study showed an unexpected role of Dmp1 in apoptosis: although it was induced to wild-type levels in Arf (Fig. 5D ).
Li et al demonstrated that low levels of Mdm2 activity induce monoubiquitination and nuclear export of p53, whereas high levels promote p53's polyubiquitination and nuclear degradation (31) .
Our results demonstrate that Dmp1 inhibits both monoubiquitination and polyubiquitination of p53, suggesting that Dmp1 can overcome Hdm2 antagonization at both high and low levels. Interestingly, in our localization studies, we found that p53 is degraded when it is co-expressed with Hdm2 in H1299 cells (p53-null, ARF wt), but is exported from the 
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